Anavex Life Sciences Corp. (NASDAQ:AVXL) was down 6.7% during mid-day trading on Monday . The stock traded as low as $3.18 and last traded at $3.19, with a volume of 488,490 shares traded. The stock had previously closed at $3.42.

Several equities research analysts have issued reports on AVXL shares. Maxim Group reiterated a “positive” rating and set a $15.00 price objective on shares of Anavex Life Sciences Corp. in a research note on Monday, April 25th. FBR & Co reiterated a “buy” rating on shares of Anavex Life Sciences Corp. in a research note on Thursday, May 12th. Finally, Zacks Investment Research upgraded shares of Anavex Life Sciences Corp. from a “hold” rating to a “buy” rating and set a $5.00 price objective for the company in a research note on Tuesday, May 31st.

The stock’s market capitalization is $113.20 million. The firm’s 50-day moving average is $5.56 and its 200 day moving average is $4.84.

Anavex Life Sciences Corp. (NASDAQ:AVXL) last announced its earnings results on Wednesday, May 11th. The company reported ($0.06) EPS for the quarter, topping the consensus estimate of ($0.16) by $0.10. Analysts anticipate that Anavex Life Sciences Corp. will post ($0.34) EPS for the current fiscal year.

Anavex Life Sciences Corp., is a clinical-stage biopharmaceutical company engaged in the development of drug candidates. The Company’s lead compounds include ANAVEX 2-73, ANAVEX PLUS, a combination of ANAVEX 2-73 with donepezil (Aricept), ANAVEX 19-144, ANAVEX 1-41, ANAVEX 7-1037, ANAVEX 3-71, ANAVEX 1079, ANAVEX 1519 and ANAVEX 1066 being developed to treat Alzheimer’s disease and other central nervous system (CNS) diseases.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.